BASILEA N |
Data / Laikas | / |
Pok. / Pok.(%) | - / |
Bid | - |
Ask | - |
Atidaryti | - |
Ankstesnį uždaryti | - |
Aukšč. | - |
Žem. | - |
APYVARTA [CHF] | - |
APYVARTA [Units] | |
Price fixings | |
ISIN | CH0011432447 |
Simbolis | BSLN |
Birža | SIX Swiss Exchange |
Rūšis | Stock |
Visos biržos
Birža | Paskutinis | APYVARTA | |
---|---|---|---|
Lang & Schwa.. | 31,70 | ![]() |
|
SIX Swiss Ex.. | 32,600 | ![]() |
20.276 |
Cboe Europe .. | 32,30 | ![]() |
1.300 |
Cboe Europe .. | 32,30 | ![]() |
700 |
Turquoise | 32,35 | ![]() |
593 |
London Domes.. | 32,35 | ![]() |
319 |
Nasdaq Other.. | 41,0000 | 40 | |
München | 32,300 | 0 | |
Berlin | 32,100 | 0 | |
Frankfurt | 32,2800 | 0 | |
gettex | 32,340 | ||
TradeGate | 30,300 | 33 | |
EUREX | Options |
Naujienos
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
08.03.2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
15.02.2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
24.01.2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
13.01.2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
11.01.2022 / 07:15 - GlobeNewswire